News | December 14, 2025
Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Subscribe To Our Newsletter & Stay Updated
